Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy

Kenneth H. Fife, Julia W. Wu, Kathleen E. Squires, D. Heather Watts, Janet W. Andersen, Darron R. Brown

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

OBJECTIVE: To determine the prevalence of human papillomavirus (HPV) DNA in cervical specimens from treatment-naive women initiating highly active antiretroviral therapy (HAART) and explore the longitudinal association of HPV DNA with CD4 count and HIV viral load (VL). METHODS: Women enrolled before HAART were evaluated at baseline, weeks 24, 48, and 96 with CD4 count, VL, and cervical swab for HPV DNA. RESULTS: The 146 subjects had a median CD4 count of 238 cells per microliter and VL of 13,894 copies per milliliter. Ninety-seven subjects (66%) had HPV DNA detected in the baseline specimen including 90 subjects (62%) positive for 1 or more high-risk HPV types. HPV DNA detection declined to 49% at week 96 and that of a high risk HPV type to 39%. The duration of follow-up was associated with decreased detection of HPV DNA of any type (P = 0.045) and of high-risk HPV types (P = 0.003). There was at most a marginal association between HAART response and loss of detection of cervical HPV DNA. CONCLUSIONS: Women initiating HAART had a high prevalence of cervical HPV DNA that declined over 96 weeks of HAART. The relationship of CD4 count and VL response to the decline of cervical HPV DNA was not strong.

Original languageEnglish (US)
Pages (from-to)274-282
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume51
Issue number3
DOIs
StatePublished - Jul 1 2009

    Fingerprint

Keywords

  • Antiretroviral therapy
  • Cervical dysplasia
  • HIV
  • Human papillomavirus

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this